# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potenti...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP...
New analysis demonstrates the impact of OCA on achievement of GGT <3.2×ULN and ALP <1.5×ULNFindings suggest that OCA has ...
Alfasigma S.p.A. ("Alfasigma") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust I...
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-review-ocaliva-started_en.pdf
B. Riley Securities analyst Mayank Mamtani downgrades Intercept Pharma (NASDAQ:ICPT) from Buy to Neutral and raises the pric...